The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
Abstract
The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI‐3, which began on August 1, 2016, is a 5‐year renewal of the current ADNI‐2 study.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 05, 2016
- Source ID
- 10.1016/j.jalz.2016.10.006
Entities
People
- Andrew J. Saykin
- Arthur W. Toga
- Clifford Jack
- Dallas P. Veitch
- Danielle Harvey
- Jennifer Salazar
- John C. Morris
- John Q. Trojanowski
- Laurel A. Beckett
- Leslie M. Shaw
- Michael W. Weiner
- Nigel J. Cairns
- Paul S. Aisen
- Robert C. Green
- Ronald C. Petersen
- The Alzheimer’s Disease Neuroimaging Initiative*
- William J. Jagust
Organizations
- Abbott Laboratories
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- AstraZeneca
- Bayer HealthCare
- BioClinica
- Bristol-Myers Squibb
- Cure Alzheimer's Fund
- Eisai
- Eli Lilly and Company
- GE HealthCare
- GSK
- Harvard Medical School
- Helen Wills Neuroscience Institute
- Hoffmann-La Roche
- Indiana University
- Innogenetics
- Loma Linda University Medical Center
- Mayo Clinic
- Medpace
- Merck & Co.
- National Institute on Aging
- National Institutes of Health
- Novartis
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- University of California
- University of California, Davis
- University of California, San Francisco
- University of Pennsylvania
- University of Southern California
- Washington University in St. Louis
- Wyeth